A study to determine clinical outcomes in refractory, relapsed, metastatic, or unresectable Fibrolamellar carcinoma patients when treated with combination systemic immunochemotherapy (5-FU, IFN and Nivolumab)
Latest Information Update: 27 Aug 2021
At a glance
- Drugs Fluorouracil (Primary) ; Interferon (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Aug 2021 New trial record